For those of you who love an indirect comparison... Post cov. BTKi management in #MCL CAR-T vs non-CART approaches from the SCHOLAR-R: overall survival analysis #lymsm #MCL #CART tandfonline.com/doi/full/10.10…

Data on patient outcomes for individuals with #CLL who are >80 is limited due to their underrepresentation in clinical trials. This study used information from the Mayo Clinic CLL Database to analyze how this population responds to treatment for CLL. bit.ly/46xNrSz

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma ashpublications.org/blood/article-…

Check out Daniel A. Ermann, MD and my new article ASCO, #ASCODailyNews on Treatment of Richter Transformation. The Tisch Cancer Institute -Richter Transformation of Chronic Lymphocytic Leukemia Is a Challenging Clinical Scenario Requiring a Personalized Approach dailynews.ascopubs.org/do/richter-tra…

Healthcare providers: Our partner, Patient Empowerment Network (PEN), is hosting a webinar addressing optimizing CLL care, with Andres Chang, MD, PhD of Emory Healthcare and Daniel A. Ermann, MD of Huntsman Cancer Institute, on Aug. 13 at 1pm ET. Learn more: bit.ly/3Lvy4Bo

New options for relapsed/refractory chronic lymphocytic leukemia: pirtobrutinib and CAR-T Therapy. Dr. Daniel Ermann discusses the latest treatment advancements and key considerations. bit.ly/3YiAlHD #CLLSM Daniel A. Ermann, MD University of Utah Health Huntsman Cancer Institute

Important new #CLL news PFS advantage for Acala-Ven+/-Obin vs ICT in 1L CLL. astrazeneca.com/media-centre/p…

New frontiers in r/r CLL: Dr. Daniel Ermann explores pirtobrutinib and CAR-T therapy. Key points on efficacy, toxicity, and patient selection. How will these options impact your treatment decisions? bit.ly/3YiAlHD #CLLSM Daniel A. Ermann, MD University of Utah Health Huntsman Cancer Institute

New options for relapsed/refractory chronic lymphocytic leukemia: pirtobrutinib and CAR-T Therapy. Dr. Daniel Ermann discusses the latest treatment advancements and key considerations. bit.ly/3YiAlHD #CLLSM Daniel A. Ermann, MD University of Utah Health Huntsman Cancer Institute

Interested in joining an awesome and collaborative Lymphoma team as a pharmacist? We're hiring! See attached posting. The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai careers.accp.com/job/2155343/cl…

Congratulations to the 2024 Young Hematology Scholar Awardees! 🏆🩸Thank you for sharing your groundbreaking work and presenting at the #HemeSummit24 this weekend in Nashville! Akriti Ayo S Falade, MD, MBA, APGD Fahmin Basher, MD, PhD Paolo Lopedote, MD Hannah Goulart Karan Chohan MD Anderson Cancer Center

In patients with advanced-stage Hodgkin’s lymphoma, nivolumab added to chemotherapy resulted in greater 2-year progression-free survival than the addition of brentuximab vedotin to chemotherapy. Full trial results: nej.md/3A00MYS

Golcadomide (CELMoD)+RCHOP 1L LBCL Jason Westin, MD FACP FASCO #ASH24: - randomized 0.2 vs 0.4 mg in dose expansion - 1-yr PFS 85% at 0.4 mg (77% at 0.2) - 90% EOT MRD- at 0.4 (73% at 0.2) - better EOT MRD- with 0.4 mg across high-risk genetics GOLSEEK-1 RCT ongoing with 0.4 mg dose. #lymsm

Our CU Lymphoma Program faculty Dr. StevenBairMD contributed to a multicenter real-world study of loncastuximab in R/R DLBCL in Haematologica. Outcomes were inferior to those described in clinical trials, with median EFS and OS of 2.1 and 4.6 months. #lymsm pubmed.ncbi.nlm.nih.gov/39540227/

Pola outcomes by Hans COO Eddie Cliff David Russler-Germain, MD/PhD #ASH24 - >700 pts in 1L & R/R cohorts - non-GC ORR/CR significantly better in R/R (60% vs 36%), but not 1L cohort - non-GCC PFS (not OS) better in R/R, not 1L - PFS better for non-GC if pola used after (not before) CAR 1/ #lymsm

WOW- practice changing MCL trial showing no benefit of autoHCT in uMRD MCL in first remission. Bravo ECOG team. Tim Fenske #ASH24

We are excited to have Daniel A. Ermann, MD from University of Utah Health Huntsman Cancer Institute, Christina Poh, MD from Fred Hutch Cancer Center UW Medicine and Travis Williams from @stlukeshealth talking about #lymphoma at #BTFHemBreast25 in Boise! Join us: education.binayfoundation.org #MedTwitter #MedX #MedEd

Mosun-pola-CHP vs pola-R-CHP 1L DLBCL - 62 pts - mosun arm: CR 73%, 2-yr PFS 71% - pola-R-CHP: CR 77%, 2-yr PFS 82% - more tx d/c in mosun arm No sig benefit of mosun-pola-CHP. #lymsm ashpublications.org/bloodadvances/…

Dr. StevenBairMD CU Lymphoma Program contributed to a multicenter study published in Haematologica about real-world outcomes of lonca in R/R DLBCL. pubmed.ncbi.nlm.nih.gov/39540227/ #lymsm

RW lonca R/R DLBCL outcomes: - 187 pts, 17% bulky, 22% HGBL, 60% prior CAR - ORR 32%, CR 14% (woof), no diff in outcomes if prior CAR - mEFS 2.1 mos, mOS 4.6 mos Dismal outcomes outside of trial setting. #lymsm pubmed.ncbi.nlm.nih.gov/39540227/